MediciNova reports additional data from completed clinical trial of MN-166
- Co announced additional clinical data from MediciNova's completed clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California.
- Highlights of the presentation include the following:
- A responder was defined as a subject who achieved the composite endpoint of less than 12 unit decline in ALSFRS-R total score at the end of the open-label extension period (i.e. average of less than one unit decline per month over entire 12 month period), and/or less than one MMT unit decline in neck and/or leg muscles at the end of the open-label extension period.
- There was a higher rate of responders in the MN-166 (ibudilast) group compared to the placebo group. 32.4% (11/34) of subjects in the MN-166 (ibudilast) group were responders compared to 11.8% of subjects in the placebo group.
- Responders showed improved survival in the 30 months post MN-166 (ibudilast) treatment.
- Subjects who completed 6 months or 12 months MN-166 (ibudilast) treatment per protocol showed improved survival in the 30 months post MN-166 (ibudilast) treatment.
No comments:
Post a Comment